CATB Catabasis Pharmaceuticals, Inc.

1.25
+0  (0%)
Previous Close 1.25
Open 1.24
Price To book 0.63
Market Cap 23.32M
Shares 18,652,000
Volume 283,528
Short Ratio 1.26
Av. Daily Volume 496,444

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 1/2 Part B top-line data released January 31, 2017 - endpoint not met. Part C data due in 2017, with an interim update in 2Q.
CAT-1004
Duchenne muscular dystrophy (DMD)

Latest News

  1. Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
  2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc.
  3. Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
  4. Catabasis Pharmaceuticals downgraded by Citigroup
  5. Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
  6. Catabasis Drops After Muscular Dystrophy Drug Fails
  7. Catabasis Pharmaceuticals Inc (CATB): What’s Next?
  8. Catabasis Pharma stock sinks 69% after negative mid-stage clinical trial results for DMD drug
  9. Catabasis shares plummet on Duchenne trial failure
  10. CATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
  11. Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
  12. Catabasis Muscular Dystrophy Drug Posts Early Win
  13. Thursday’s Top Biopharma Movers
  14. Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug
  15. Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology
  16. Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
  17. Will Catabasis Pharmaceuticals (CATB) Continue to Surge Higher?
  18. Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
  19. Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
  20. Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight